Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Quinacrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.96 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.96 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.96 |
| ▸ | CHRM5 known ✓ | P08912 | 1/20 | 0.96 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.96 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.96 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.96 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.96 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.96 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.96 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.96 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.96 |
| ▸ | HRH2 known ✓ | P25021 | 1/20 | 0.96 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.96 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.96 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.96 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.96 |
| ▸ | SCN1A known ✓ | P35498 | 1/20 | 0.96 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.96 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quinacrine SCHEMBL25334547 | 1.00 | USP2 (1.00) | USP2KDM4EMEN1LMNAKMT2A | |
| Quinacrine SCHEMBL7147117 | 1.00 | USP2 (1.00) | USP2KDM4EMEN1LMNAKMT2A | |
| Quinacrine SCHEMBL7147115 | 1.00 | USP2 (1.00) | USP2KDM4EMEN1LMNAKMT2A | |
| Quinacrine SCHEMBL162378 | 1.00 | USP2 (1.00) | USP2KDM4EMEN1LMNAKMT2A | |
| Quinacrine SCHEMBL30416460 | 1.00 | USP2 (1.00) | USP2KDM4EMEN1LMNAKMT2A | |
| Quinacrine SCHEMBL28651594 | 0.99 | USP2 (0.98) | USP2KDM4EMEN1LMNAKMT2A | |
| Quinacrine SCHEMBL30153780 | 0.99 | USP2 (1.00) | USP2KDM4EMEN1LMNAKMT2A | |
| Quinacrine SCHEMBL162379 | 0.99 | USP2 (1.00) | USP2KDM4EMEN1LMNAKMT2A | |
| Quinacrine SCHEMBL15061349 | 0.99 | USP2 (1.00) | USP2KDM4EMEN1LMNAKMT2A | |
| Quinacrine SCHEMBL33693 | 0.99 | USP2 (1.00) | USP2KDM4EMEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4536236-A2 | METHODS OF MODULATING ATXN2 EXPRESSION | University of Utah Research Foundation (US) | 2025-04-16 | — | — | EP | claimed |
| WO-2024102612-A1 | COMPOUNDS AND METHODS FOR IDENTIFYING COMPOUNDS FOR MODULATING GLUCOSE TRANSPORT | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-05-16 | — | — | WO | claimed |
| WO-2023239747-A2 | METHODS OF MODULATING ATXN2 EXPRESSION | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2023-12-14 | — | — | WO | claimed |
| EP-3677259-A1 | USE OF ARACHIDONYL TRIFLUOROMETHYL KETONE | Mosaiques Diagnostics And Therapeutics AG (DE) | 2020-07-08 | — | — | EP | claimed |
| US-20110224141-A1 | METHODS AND RELATED COMPOSITIONS FOR THE TREATMENT OF CANCER | STC.UNM (US) | 2011-09-15 | — | — | US | claimed |
| WO-2009148623-A2 | METHODS AND RELATED COMPOSITIONS FOR THE TREATMENT OF CANCER | STC.UNM (US) | 2009-12-10 | — | — | WO | claimed |
| US-20060034731-A1 | Sensor arrays for detecting analytes in fluids | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2006-02-16 | — | — | US | claimed |
| US-20260137707-A1 | METHODS OF MODULATING ATXN2 EXPRESSION | UNIV OF UTAH RESEARCH FOUNDATION (US) | 2026-05-21 | — | — | US | disclosed |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | Didenko, Kirill (US) | 2025-07-03 | — | — | US | disclosed |
| EP-4536236-A2 | METHODS OF MODULATING ATXN2 EXPRESSION | University of Utah Research Foundation (US) | 2025-04-16 | — | — | EP | disclosed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| WO-2024102612-A1 | COMPOUNDS AND METHODS FOR IDENTIFYING COMPOUNDS FOR MODULATING GLUCOSE TRANSPORT | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-05-16 | — | — | WO | disclosed |
| WO-2023239747-A2 | METHODS OF MODULATING ATXN2 EXPRESSION | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20090036387-A1 | NOVEL CHEMICAL ENTITIES AFFECTING NEUROBLASTOMA TUMOR-INITIATING CELLS | THE HOSPITAL FOR SICK CHILDREN (CA) | 2009-02-05 | — | — | US | disclosed |
| US-20080038770-A1 | Cancer Stem Cells And Uses Thereof | HOSPITAL FOR SICK CHILDREN (CA) | 2008-02-14 | — | — | US | disclosed |
| WO-2007079293-A2 | CANCER STEM CELLS AND USES THEREOF | HOSPITAL FOR SICK CHILDREN (CA) | 2007-07-12 | — | — | WO | disclosed |
| US-20070123448-A1 | Novel chemical entities affecting neuroblastoma tumor-initiating cells | THE HOSPITAL FOR SICK CHILDREN (CA) | 2007-05-31 | — | — | US | disclosed |
| US-20060034731-A1 | Sensor arrays for detecting analytes in fluids | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2006-02-16 | — | — | US | disclosed |
| US-20010046662-A1 | Method of inactivating pathogens in a red blood cell-containing composition | THE AMERICAN NATIONAL RED CROSS | 2001-11-29 | — | — | US | disclosed |
| WO-2001078792-A1 | METHOD OF INACTIVATING PATHOGENS | THE AMERICAN NATIONAL RED CROSS (US) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137707-A1 | METHODS OF MODULATING ATXN2 EXPRESSION | ATXN2, ATXN2L, ATP6V1B2 | CHRM2 4196/4885CHRM4 4376/4885HTR1A 2508/4885 |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | ACE2, FURIN, SARS1 | CHRM2 4445/4885CHRM4 3950/4885HTR1A 2708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.